Advertisement

Topics

Trastuzumab Deruxtecan Efficacious in Breast Cancer Across Varying HER2 Levels

12:08 EDT 13 Jun 2018 | OncLive

Long-term findings from a phase I study of trastuzumab deruxtecan showed that the investigational HER2-targeting antibody-drug conjugate had antitumor activity in multiple tumor types that expressed HER2 at varying levels. 

Original Article: Trastuzumab Deruxtecan Efficacious in Breast Cancer Across Varying HER2 Levels

NEXT ARTICLE

More From BioPortfolio on "Trastuzumab Deruxtecan Efficacious in Breast Cancer Across Varying HER2 Levels"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...